MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Company business development and clinical team members will attend the event scheduled for January 8–10, 2026 at the Chateaux Deer Valley in Park City, Utah.
This participation highlights MetaVia's engagement with the cardiometabolic and clinical research community but does not include financial or clinical readouts in this announcement.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MTVA declined 2.07%, reflecting a moderate negative market reaction. This price movement removed approximately $438K from the company's valuation, bringing the market cap to $21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with LPCN up 11.75%, THAR up 4.02%, PULM up 2.63%, SYBX up 1.68%, and PRTG down 10.39%. Only THAR appeared on the momentum scanner, suggesting today’s weakness in MTVA is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Listing compliance | Positive | +11.6% | Regained compliance with Nasdaq minimum bid requirement and closed related matter. |
| Dec 02 | Reverse stock split | Negative | -20.1% | 1-for-11 reverse split to address Nasdaq listing requirements and adjust share count. |
| Nov 07 | Phase 2a data | Positive | +6.8% | Positive Phase 2a results for vanoglipel in presumed MASH with metabolic benefits. |
| Nov 06 | Q3 earnings update | Negative | -15.0% | Q3 2025 results with going-concern language despite pipeline and cash update. |
| Nov 04 | Conference data | Positive | +8.0% | New Phase 1 and preclinical data on DA-1726 presented at ObesityWeek 2025. |
Recent news has consistently seen price moves that align with the underlying news tone, both positive clinical updates and financing/listing actions.
Over the past few months, MetaVia has combined clinical progress with capital-structure moves. Positive data for vanoglipel and DA-1726 in late 2025 coincided with notable price gains, while the 1-for-11 reverse split on Dec 4, 2025 and going-concern language in Q3 2025 results were followed by declines. Regaining Nasdaq minimum bid compliance on Dec 19, 2025 saw a positive reaction. Today’s conference participation fits the pattern of ongoing visibility efforts alongside earlier clinical milestones and financing activities.
Market Pulse Summary
This announcement highlights MetaVia’s continued engagement with the MASH community and cardiometabolic stakeholders through the 10th Annual MASH-TAG 2026 Conference on January 8–10, 2026. In recent months, the company paired positive data for vanoglipel and DA-1726 with significant capital-structure steps, including a 1-for-11 reverse split and an at-the-market offering of up to $2.3M. Investors may watch for further clinical updates, funding developments, and Nasdaq listing status as key markers of future progress.
Key Terms
cardiometabolic medical
AI-generated analysis. Not financial advice.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-and-sponsor-the-10th-annual-mash-tag-2026-conference-302649854.html
SOURCE MetaVia Inc.
FAQ
When will MetaVia (MTVA) attend the 10th Annual MASH-TAG 2026 Conference?
Where is the MASH-TAG 2026 Conference that MetaVia (MTVA) is sponsoring?
Which MetaVia teams will be present at MASH-TAG 2026 for MTVA?
Does MetaVia (MTVA) announce any clinical data or financial guidance at MASH-TAG 2026?
How can investors follow MetaVia (MTVA) participation at MASH-TAG 2026?
